|By PR Newswire||
|February 25, 2014 02:57 PM EST||
NEW YORK, Feb. 25, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NasdaqGS: ICPT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 237.
The investigation concerns whether Intercept and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On January 10, 2014, after the market closed, the National Institutes of Health's ("NIH") National Institute of Diabetes and Digestive and Kidney Diseases issued a press release stating that while the efficacy primary endpoint for the Company's primary drug compound, known as obeticholic acid ("OCA"), in the Phase 2 study had already been met, participants in the study who received the drug suffered disproportionate levels of lipid abnormalities.
On this news, shares of Intercept fell over $81.00 per share to $364.36 or more than 18.20%, on February 10, 2014.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
SOURCE Pomerantz LLP
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 3, 2016 01:45 AM EST Reads: 694
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, showed how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningful f...
Dec. 3, 2016 01:45 AM EST Reads: 4,518
Dec. 3, 2016 01:15 AM EST Reads: 841
Dec. 3, 2016 12:30 AM EST Reads: 1,517
Dec. 3, 2016 12:15 AM EST Reads: 1,745
Dec. 2, 2016 11:15 PM EST Reads: 887
Dec. 2, 2016 11:15 PM EST Reads: 1,673
Dec. 2, 2016 10:30 PM EST Reads: 1,723
Dec. 2, 2016 08:30 PM EST Reads: 4,973
Dec. 2, 2016 08:30 PM EST Reads: 362
Dec. 2, 2016 08:15 PM EST Reads: 1,558
Dec. 2, 2016 07:00 PM EST Reads: 3,918
Dec. 2, 2016 06:45 PM EST Reads: 3,984
Dec. 2, 2016 06:30 PM EST Reads: 1,478
Dec. 2, 2016 05:15 PM EST Reads: 372